Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. This is the first anti-IL-17 biologic approved for
Randomized trials typically get top billing at ACR Convergence, but the past three years have seen “target trial emulations” land coveted plenary sessions and oral abstracts. These are not actually trials; instead, they are a new-ish approach to generating causal inferences from observational
Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:
Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms. Jones calls you with a reported second PMR symptom relapse at a 6 milligram
It's a wrap on Day 2 at ACR Convergence 2026. These five abstracts caught my eye.
